Apotea AB (publ) (STO:APOTEA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 8.00B -16.0% |
| Revenue (ttm) | 7.39B +9.1% |
| Net Income | 236.30M -0.6% |
| EPS | 2.27 -1.5% |
| Shares Out | 104.07M |
| PE Ratio | 33.88 |
| Forward PE | 25.94 |
| Dividend | 0.60 (0.78%) |
| Ex-Dividend Date | May 27, 2026 |
| Volume | 175,996 |
| Open | 76.90 |
| Previous Close | 76.90 |
| Day's Range | 74.30 - 76.95 |
| 52-Week Range | 54.42 - 122.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 90.00 (+20.16%) |
| Earnings Date | Jul 17, 2026 |
About Apotea AB
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weigh... [Read more]
Financial Performance
In 2025, Apotea AB's revenue was 7.21 billion, an increase of 10.15% compared to the previous year's 6.54 billion. Earnings were 228.70 million, an increase of 6.42%.
Financial StatementsNews
Apotea AB Earnings Call Transcript: Q1 2026
Q1 delivered 10.5% revenue growth and a 5.2% operating margin, with gross margin at a record 28.3% due to successful campaigns and improved procurement. Growth initiatives included a Norway launch and ramp-up at Varberg, while financial targets remain cautious amid global uncertainties.
Apotea AB Quarterly report: Q1 2026
Apotea AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
Apotea AB Slides: Q1 2026
Apotea AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Apotea AB Earnings Call Transcript: Q4 2025
Q4 saw 7% revenue growth but weaker profitability due to campaign intensity and Varberg ramp-up costs. Full-year growth was strong at 10.1%, with major investments completed and new growth initiatives underway, including expansion into Norway.
Apotea AB Quarterly report: Q4 2025
Apotea AB has published its Q4 2025 quarterly earnings report on February 4, 2026.
Apotea AB Slides: Q4 2025
Apotea AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 4, 2026.
Apotea AB Annual report: Q4 2025
Apotea AB has published its Q4 2025 annual report on February 4, 2026.
Apotea AB Earnings Call Transcript: Q3 2025
Q3 saw 8.9% revenue growth, a 5% EBIT margin, and strong Rx sales, supported by the successful Varberg warehouse launch and efficiency gains. Net cash reached SEK 98 million, with a focus now shifting to external growth and leveraging new capacity.
Apotea AB Quarterly report: Q3 2025
Apotea AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Apotea AB Slides: Q3 2025
Apotea AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Apotea AB Earnings Call Transcript: Q2 2025
Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.
Apotea AB Quarterly report: Q2 2025
Apotea AB has published its Q2 2025 quarterly earnings report on July 18, 2025.
Apotea AB Slides: Q2 2025
Apotea AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 18, 2025.